| Jing, Hongmei |
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 85 | RoW | Pomalidomide, Dexamethasone | Qilu Pharmaceutical Co., Ltd. | Multiple Myeloma, Recurrent or Refractory | 06/22 | 12/23 | | |
| Recruiting | 3 | 240 | RoW | Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone | Nanjing IASO Biotechnology Co., Ltd. | Multiple Myeloma | 08/27 | 12/30 | | |
NCT06363994: A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL |
|
|
| Recruiting | 3 | 476 | RoW | Orelabrutinib, Bendamustine Injection, Rituximab, Orelabrutinib Placebo | InnoCare Pharma Inc. | Mantle Cell Lymphoma | 06/31 | 06/32 | | |
| Recruiting | 3 | 357 | Europe, Japan, US, RoW | Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib | GlaxoSmithKline | Multiple Myeloma | 01/24 | 05/29 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 3 | 440 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
ICP-CL-01203, NCT06378138: ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2/3 | 226 | RoW | ICP-248, Orelabrutinib | Beijing InnoCare Pharma Tech Co., Ltd. | Hematologic Malignancies | 11/30 | 07/31 | | |
NCT06511895: AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) |
|
|
| Recruiting | 2 | 150 | RoW | AZD4205 | Dizal Pharmaceuticals | Peripheral T Cell Lymphoma | 05/25 | 12/26 | | |
| Active, not recruiting | 2 | 59 | RoW | CD19-targeted Chimeric Antigen Receptor (CAR) T Cells | Shanghai Ming Ju Biotechnology Co., Ltd. | Mantle Cell Lymphoma | 10/23 | 08/28 | | |
NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 60 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Non-Hodgkin's Lymphoma | 03/24 | 09/25 | | |
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
| Not yet recruiting | 2 | 30 | RoW | R-EPOCH in Combination With Ibrutinib | Institute of Hematology & Blood Diseases Hospital, Xian-Janssen Pharmaceutical Ltd. | Richter Transformation | 08/24 | 08/25 | | |
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis |
|
|
| Active, not recruiting | 2 | 112 | Europe, US, RoW | Selinexor, Physician's Choice Treatment | Karyopharm Therapeutics Inc | Myelofibrosis | 01/25 | 01/25 | | |
|
|
NCT05978739: Evaluating Different Doses of Orelabrutinib in MCL |
|
|
| Recruiting | 2 | 40 | RoW | Orelabrutinib High dose, Orelabrutinib Low dose | InnoCare Pharma Inc., Beijing InnoCare Pharma Tech Co., Ltd. | Mantle Cell Lymphoma | 02/25 | 05/25 | | |
NCT05155215: Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma |
|
|
| Not yet recruiting | 1/2 | 68 | NA | IM19 CAR-T cells, Cyclophosphamide, Fludarabine | Beijing Immunochina Medical Science & Technology Co., Ltd. | Lymphoma, Lymphoma, Mantle-Cell, Neoplasms by Histologic Type, Neoplasms, Lymphoproliferative Disorders | 12/22 | 02/23 | | |
NCT04735575: A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma |
|
|
| Recruiting | 1/2 | 66 | RoW | EMB-06 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Relapsed or Refractory Multiple Myeloma | 12/23 | 03/25 | | |
| Active, not recruiting | 1/2 | 121 | RoW | CAR-BCMA T Cells | CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Multiple Myeloma | 12/24 | 12/25 | | |
| Completed | 1/2 | 272 | Europe, Canada, Japan, US, RoW | Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone | Takeda, Takeda Development Center Americas, Inc. | Multiple Myeloma | 07/24 | 11/24 | | |
NCT04494503: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL |
|
|
| Recruiting | 1/2 | 123 | RoW | APG-2575, Rituximab, Ibrutinib | Ascentage Pharma Group Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 12/25 | | |
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
|
|
| Recruiting | 1/2 | 39 | RoW | 400mg of TQB3909 tablets, 600mg of TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Mantle Cell Lymphoma | 12/24 | 12/24 | | |
NCT05565807: Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 84 | RoW | STI-6129 | Zhejiang ACEA Pharmaceutical Co. Ltd. | Relapsed or Refractory Multiple Myeloma | 03/25 | 02/27 | | |
NCT05299424: A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 48 | RoW | CM336_group 1, CM336_group 2a, CM336_group 2b, CM336_group 3a, CM336_group 3b, CM336_group 4a, CM336_group 4b, CM336_group 5, CM336_group 6a, CM336_group 6b, CM336_group 7, CM336_group 8a, CM336_group 8b, CM336_group 9, CM336_RP2D | Keymed Biosciences Co.Ltd | Multiple Myeloma | 12/26 | 12/26 | | |
NCT04818372: Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma |
|
|
| Recruiting | 1 | 87 | RoW | CM313-Dose escalation, CM313, Dexamethasone, Lenalidomide | Keymed Biosciences Co.Ltd | Multiple Myeloma, Lymphoma | 01/23 | 04/23 | | |
NCT04993690: A Study of LP-168 in Participants with Relapse or Refractory B-Cell Lymphoma |
|
|
| Recruiting | 1 | 200 | RoW | LP-168 tablet | Guangzhou Lupeng Pharmaceutical Company LTD. | B-cell Lymphoma | 12/24 | 06/25 | | |
| Recruiting | 1 | 191 | RoW | ICP-248, ICP-248+Orelabrutinib | Beijing InnoCare Pharma Tech Co., Ltd. | Hematological Malignancies | 08/25 | 10/26 | | |
NCT04606433: Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 41 | RoW | GNC-038 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | 06/25 | 11/25 | | |
| Recruiting | 1 | 75 | RoW | Keynatinib, TL007 | Medolution Ltd. | Lymphoma, B-Cell | 10/27 | 04/28 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
| Completed | N/A | 1006 | RoW | | Takeda | Lymphoma | 07/24 | 07/24 | | |
NCT06450067: Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia |
|
|
| Recruiting | N/A | 200 | RoW | | Juventas Cell Therapy Ltd. | B-cell Acute Lymphoblastic Leukemia | 06/26 | 06/29 | | |
| Active, not recruiting | N/A | 482 | RoW | | Takeda | Multiple Myeloma, Neoplasms, Plasma Cell | 09/25 | 09/25 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
| Cao, Baoshan |
TQB2450-III-09, NCT04964479: A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) |
|
|
| Recruiting | 3 | 375 | RoW | TQB2450 injection, Anlotinib Hydrochloride Capsules, Pembrolizumab injection, Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 12/22 | 03/23 | | |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
HLX10-006-GCneo, NCT04139135: A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer |
|
|
| Recruiting | 3 | 642 | RoW | HLX10, Recombinant humanized anti-PD-1 monoclonal antibody injection, Placebos | Shanghai Henlius Biotech | Gastric Cancer | 10/23 | 10/24 | | |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT04750083: HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer |
|
|
| Recruiting | 2/3 | 700 | RoW | HX008, Pembrolizumab, pemetrexed, cisplatin/carboplatin | Taizhou Hanzhong biomedical co. LTD | Nonsquamous Non-small Cell Lung Cancer | 09/22 | 09/23 | | |
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 114 | RoW | TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel | TransThera Sciences (Nanjing), Inc. | Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer | 09/24 | 12/24 | | |
NCT04121286: A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China |
|
|
| Recruiting | 1 | 24 | RoW | JAB-3312 | Jacobio Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Other Solid Tumors | 12/23 | 12/23 | | |
